Clay Siegall, Morphimmune CEO

Up­dat­ed: Ex-Seagen chief Clay Sie­gall emerges as CEO of pri­vate biotech

Clay Sie­gall will be back in the CEO seat, tak­ing the helm of a pri­vate start­up work­ing on tar­get­ed can­cer ther­a­pies.

It’s been al­most a year since Sie­gall re­signed from Seagen, the biotech he co-found­ed and led for more than 20 years, in the wake of do­mes­tic vi­o­lence al­le­ga­tions by his then-wife. His even­tu­al suc­ces­sor, David Ep­stein, sold the com­pa­ny to Pfiz­er in a $43 bil­lion deal un­veiled last week.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters